Clinical Trials Browser

Approved for marketing × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all

NCT01592136 2018-02-06

Expanded Access Program of Ponatinib

Approved for marketing

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00905593 2012-07-18

ENACT

Approved for marketing

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive